Alluvi, formerly LY3414901, represents a exciting advancement in metabolic management. This twin -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) target agonist demonstrates remarkable effectiveness in early clinical data, with considerable slimming o